Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Expedia Group Inc (EXPE) Price & Performance

Quest Diagnostics IncTrade
Expedia Group IncTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Expedia Group Inc — how do they compare? Quest Diagnostics Inc trades at $237.08 (market cap $26.21B), while Expedia Group Inc trades at $318.52 (market cap $38.53B). The key difference: Expedia Group Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.

DGXEXPE
Market Cap
$26.21B$38.53B
Sector
HealthConsumer Cyclical
52-Week High
$238.50$321.07
52-Week Low
$173.49$188.51
Enterprise Value
$31.97B$37.09B
Dividend Yield
1.45%0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.

DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.

Expedia Group Inc

Expedia Group (EXPE) trades at $314.01, up 1.07% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $5.76 beating estimates by 10.3% and revenue growth accelerating to 14% year-over-year. Recent earnings show continued B2B momentum and AI-driven efficiency improvements, with the company raising full-year revenue guidance to $16.05-16.22 billion. Valuation metrics remain reasonable with P/E of 20.19 and EV/EBITDA of 10.04, while profitability metrics show impressive ROE of 199.12% and net margin of 12.97%.

Expedia presents a favorable investment case with strong earnings momentum, strategic AI integration, and upward guidance revisions. The stock trades near analyst consensus target of $322.95 with 47% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include travel demand sensitivity to economic conditions and competitive pressures in online travel. The combination of fundamental strength and technical momentum supports a constructive outlook for patient investors.

Returns comparison

Trailing returns across standard periods

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About Expedia Group Inc

Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.

Read more on EXPE